Effect of statins on skeletal muscle function

Circulation

Volumn 127, Issue 1, 2013, Pages 96-103

  Parker, Beth A ^a   Capizzi, Jeffrey A ^a   Grimaldi, Adam S ^a   Clarkson, Priscilla M ^b   Cole, Stephanie M ^b   Keadle, Justin ^b   Chipkin, Stuart ^b   Pescatello, Linda S ^c   Simpson, Kathleen ^c   Michael White, C ^c   Thompson, Paul D ^a  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

atorvastatin; exercise test; hydroxymethylglutaryl CoA reductase inhibitors; muscle strength; myopathy

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CALCIFEDIOL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; EXERCISE; FATIGUE; FEMALE; FOLLOW UP; GRIP STRENGTH; HUMAN; LEG CRAMP; LEG PAIN; MALE; MUSCLE FUNCTION; MUSCLE STRENGTH; MYALGIA; NORMAL HUMAN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; SEROLOGY; SKELETAL MUSCLE;

ADULT; CREATINE KINASE; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULOSKELETAL PAIN; PLACEBOS; PYRROLES; YOUNG ADULT;

EID: 84872093145     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.136101     Document Type: Article

References (25)

1. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
2. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.
3. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2002:56.
4. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
5. Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21:324-328.
6. Thompson PD, Parker BA, Clarkson PM, Pescatello LS, White CM, Grimaldi AS, Levine BD, Haller RG, Hoffman EP. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol. 2010;13:104-111.
7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
8. Katsiaras A, Newman AB, Kriska A, Brach J, Krishnaswami S, Feingold E, Kritchevsky SB, Li R, Harris TB, Schwartz A, Goodpaster BH. Skeletal muscle fatigue, strength, and quality in the elderly: the Health ABC Study. J Appl Physiol. 2005;99:210-216.
9. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients:-the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414.
10. Phillips PS, Haas RH. Observations from a statin myopathy clinic. Arch Intern Med. 2006;166:1232-1233.
11. El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, Saadeh R, Saydam M. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44:877-881.
12. Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30:541-553.
13. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
14. Maningat P, Breslow JL. Needed: pragmatic clinical trials for statin-intolerant patients. N Engl J Med. 2011;365:2250-2251.
15. Lee YH, Choi SJ, Ji JD, Song GG. Serum creatine kinase in patients with rheumatic diseases. Clin Rheumatol. 2000;19:296-300.
16. Radi ZA, Koza-Taylor PH, Bell RR, Obert LA, Runnels HA, Beebe JS, Lawton MP, Sadis S. Increased serum enzyme levels associated with Kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol. 2011;179:240-247.
17. Hanai J, Cao P, Tanksale P, Imamura S, Koshimizu E, Zhao J, Kishi S, Yamashita M, Phillips PS, Sukhatme VP, Lecker SH. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest. 2007;117:3940-3951.
18. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005;25:2560-2566.
19. Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, D'Hemecourt PA, Thompson PD. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109:282-287.
20. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, Hoppeler H, Breil F, Draeger A. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;18:E11-E18.
21. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis. 2000;150:121-127.
22. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004;177:183-188.
23. Mullen PJ, Zahno A, Lindinger P, Maseneni S, Felser A, Krähenbühl S, Brecht K. Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta. 2011;1813:2079-2087.
24. Wu JS, Buettner C, Smithline H, Ngo LH, Greenman RL. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve. 2011;43:76-81.
25. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19:259-263.